02_Science.
Precision SSE Technology.
02_Science.
Synthetic Super-Enhancers (SSEs).
The Key to Precision.
At the heart of our technology are Synthetic Super-Enhancers (SSEs), engineered DNA elements that are only activated in the diseased cell states.
SSEs act as docking stations for transcription factors uniquely expressed in aggressive cancer or diseased cells, allowing for highly selective and potent gene control.
Discover
_Discover.
Our Breakthrough Technology.
Our viral immunotherapy technology uses highly specific SSEs, activated only in aggressive cancer cells, to control the expression of two therapeutic payloads within an AAV vector system.
The payloads work in tandem: one produces an enzyme converting an oral prodrug into a cytotoxic agent, while the other generates IL-12 to stimulate an immune response against the tumour.
The therapy is injected directly into the tumour via an AAV vector, the Trojan Horse, which not only eliminates the primary tumour but also establishes long-term immune memory preventing tumour regrowth.
MoA animation by Visual Science.
_Approach.
A Three-Pronged Attack on Cancer.
Trogenix’s revolutionary approach to cancer treatment is based on three key strategies.
01_
Precision Cell Killing.
Cytotoxic payload kills cancer cells.
02_
Immune Activation.
Creates “hot” tumour microenvironment and immunological memory.
03_
Trojan Horse Mechanism.
Guards against tumour plasticity/escape.
Implications for Cancer Therapy.
-
Potential for “one and done” curative approach.
-
Long-term protection against recurrence.
-
One product, personalised immuno-therapy.
-
Applicable across multiple cancer types.
_Platform.
Odysseus® Platform.
Trogenix’s SSEs (Synthetic Super Enhancers) are engineered DNA regulatory elements that are only activated in diseased cell states. They act as docking stations for specific transcription factors that are exclusively expressed in aggressive cancer or diseased cells, thereby enabling precise gene control.
The Odysseus® platform combines advanced genomics, profiling, bioinformatics, and machine learning to identify key transcription factors and design appropriate enhancer fragments for SSE construction.
The compact size of SSEs allows them to be packaged into AAV vectors along with therapeutic payloads, and the Odysseus® platform enables design and validation of SSEs for any human cell type or disease state, particularly cancers.
MoA animation by Visual Science.
Key Features of Our SSE Technology.
- Exquisite Precision.
Our engineered DNA elements enable unprecedented selective control over gene expression in cancer cells.
- Self-Dosing Control.
Treatment intensity and duration automatically scales with the number of disease cells present.
- Cancer State Targeting.
SSEs respond to specific combinations of transcription factors unique to aggressive cancer and therapy-resistant states.
- Rapid Adaptation.
Our modular platform allows rapid deployment and engineering of new genetic medicines Combination Payload Delivery SSEs drive both targeted cell killing and immune system activation for maximum therapeutic impact and long-term protection
- Built-in Safety.
Activity naturally extinguishes as cancer cells are killed or exit their aggressive state.
- Beyond Cancer.
Our versatile platform technology extends to regenerative medicine, tissue repair, and age-related diseases.
_Programme.
Glioblastoma_Our Lead Programme.
Our lead programme is in glioblastoma (GBM), one of the most aggressive forms of brain cancer and an area of extremely high unmet medical need.
Current treatments offer limited efficacy.
Affects
200,000
GBM affects approximately two hundred thousand people globally each year.
Incidence
25
Only twenty five percent of patients survive beyond one year.
Overall
15
With a median overall survival of just fifteen months.
After decades of intensive research, we finally have the advanced tools and deep understanding necessary to tackle this formidable challenge.
Trogenix’s GBM therapy has shown curative potential in preclinical studies, demonstrating –
- Complete responses with no toxicity and no relapse
- Potent innate and adaptive immune responses
- Evidence of persistent anti-tumour immunity
- Efficacy in late-stage tumours reflecting real-world clinical presentation
- Validation of transduction and expression in patient tumour tissue
By targeting the fundamental identity and aggressive behaviours of cancer cells, we’re developing a pipeline of precision therapies that could transform treatment paradigms.
03_Pipeline